Promising drug combo targets rare penile cancer in first major trial
NCT ID NCT07110038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, enfortumab vedotin and avelumab, as a first treatment for men with advanced or metastatic penile cancer that cannot be cured by surgery. The goal is to see if the drugs shrink tumors and help patients live longer. About 25 men will take part in this early-stage trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE SQUAMOUS CELL CARCINOMA (PSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Caritas St. Josef Medical Center
RECRUITINGRegensburg, Germany
-
Rostock University Medical Center
RECRUITINGRostock, Germany
-
Technical University of Munich, University Hospital Munich
RECRUITINGMunich, Germany
-
University Hospital Mannheim
RECRUITINGMannheim, Germany
-
University Hospital Tübingen
RECRUITINGTübingen, Germany
-
University Hospital and Medical Faculty, Heinrich-Heine-University, Düsseldorf
RECRUITINGDüsseldorf, Germany
-
University Medical Center of Johannes Gutenberg-University
RECRUITINGMainz, Germany
-
Universitätsklinikum Carl Gustav Carus
RECRUITINGDresden, Germany